• DAPI Nuclear Stain: Identity and Evidence Scope

  2026-10-13

  DAPI (4′,6-Diamidino-2-Phenylindole) is documented here as a blue-fluorescent DNA-binding nuclear visualization dye supplied by APExBIO as product K2402. The available evidence supports describing its intended conceptual scope—nuclear labeling and endpoint assessment of membrane compromise—but does not provide an independent study, outcome statistics, or validated performance comparison.

• DiD as a Membrane Readout in Preclinical Research

  2026-10-13

  DiD, also called DiDC 18 (5), is described by APExBIO as a red fluorescent lipophilic membrane probe for conceptual applications including cell membrane staining, neuronal tracing dye studies, cell migration tracking, and immunofluorescence-compatible imaging. The supplied diabetic-periodontitis study provides preclinical evidence for a separate ROS-responsive nanoparticle–hydrogel strategy, but it does not establish that DiD was used or that membrane labeling validates mitochondrial repair or therapeutic benefit.

• PML, HIF1AN and BMSC Osteogenic Differentiation

  2026-10-12

  A source-grounded overview of a 2025 study linking PML, HIF1AN ubiquitination, the HIF1α/SOD3 axis and PI3K/AKT signaling to osteogenic differentiation in bone marrow mesenchymal stem cells, with emphasis on evidence limits and product provenance.

• Ketone Bodies and Stroke Neuroprotection: Study Overview

  2026-10-12

  A source-grounded overview of a 2024 ACS Chemical Neuroscience study examining whether remote ischemic postconditioning protects against ischemic stroke through ketone-body metabolism and reduced ferroptosis. The findings support a preclinical mechanistic association but do not establish 3-hydroxybutyrate (BHBA) as the sole mediator or demonstrate clinical efficacy.

• Protein A/G Co-IP: Evidence and Applications

  2026-10-09

  This overview examines the research context for the Protein A/G Magnetic Co-IP/IP Kit and recombinant Protein A/G magnetic beads, with emphasis on co-immunoprecipitation of protein complexes, protein-protein interaction analysis, and evidence interpretation. It distinguishes supplier-described capabilities from findings reported in a 2026 Trichoderma–peanut study, explaining how affinity capture may support mechanistic research without establishing causality by itself. Applicability boundaries, evidence strength, provenance, and limitations are addressed throughout.

• Gefitinib (ZD1839): From EGFR to Tumor Context

  2026-10-09

  Gefitinib is most informative when treated not simply as an EGFR inhibitor, but as a context-sensitive pharmacological probe. This article connects its mechanism with findings from patient-derived gastric cancer assembloids, clarifies the evidence boundaries, and outlines how translational researchers can interpret tumor–stroma effects without overstating clinical relevance.

• DRB and ac4C RNA Regulation: Evidence and Limits

  2026-10-08

  This overview places 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) in context as a broad transcriptional elongation and CDK perturbant, then compares that pharmacological profile with a 2026 Advanced Science study of ac4C-modified lncRNA Gm26917 in female germline stem cells. It emphasizes what is reported, what remains untested, and where interpretation must remain model-specific.

• Periostin Regulation in HER2-Positive Breast Cancer

  2026-10-08

  Labrèche et al. identify a context-dependent regulatory network in which FGFR, TGFβ, PKC, and PI3K/AKT signaling jointly control periostin expression in Neu-positive breast cancer cells. The study links epithelial acquisition of periostin to pathway cross talk rather than a single linear signal, while also showing why findings from murine models and selected cell systems require cautious translation to human disease.

• O-propargyl-puromycin and B-Cell Translation

  2026-10-07

  O-propargyl-puromycin (OPP) can provide a conceptual readout of nascent protein synthesis, but its relevance to Pcbp1-dependent B-cell biology must be tested rather than assumed. This overview compares OPP with complementary methods and defines key evidence limitations.

• Multimodal Allosteric Control of Cas13d

  2026-10-07

  The reference study identifies a domain-insertion hotspot in RfxCas13d that supports control by blue light or rapamycin analogs without splitting the nuclease into separate protein fragments. Its OptoCas13d and ChemoCas13d variants enable stimulus-dependent RNA knockdown, establishing a framework for more spatially and temporally precise RNA biology while leaving questions about generality, durability, and collateral activity open.

• vIRD, RIPK3 Degradation, and Viral Inflammation

  2026-10-06

  Liu et al. identify a class of orthopoxvirus proteins that recruits host SCF ubiquitin-ligase machinery to degrade RIPK3, suppressing necroptosis while shaping viral replication and inflammation. The study combines molecular, genetic, and mouse-model evidence to connect vIRD activity with pathogen–host evolution and disease severity.

• WST-8 Glucose Uptake Assay: Evidence and Limits

  2026-10-06

  A source-grounded overview of the WST-8 Glucose Uptake Assay Kit, including its 2-deoxyglucose-based readout, potential research contexts, evidence strength, and important interpretation limits.

• Camostat Mesilate: Reading Protease Evidence

  2026-10-05

  Camostat Mesilate is a trypsin-like protease inhibitor whose ENaC, plasmin–TGF-β, and fibrosis findings require careful mechanistic interpretation. This article uses a recent macrocyclic TMPRSS2 study to clarify what the evidence supports, what it does not, and how to compare distinct inhibitor classes without overextending conclusions.

• YTHDF1 Phase Separation and SSC Fate Transition

  2026-10-05

  Fang et al. show that liquid-liquid phase separation by the m6A reader YTHDF1 helps drive spermatogonial stem cells toward neural stem cell-like states through the IκB–NF-κB–CCND1 axis. The study connects RNA modification, translational control, and biomolecular condensation in a cell-fate transition, while also highlighting important limits on how broadly the findings can be applied.

• Genotyping Kit for Target Alleles: Evidence to Insight

  2026-10-04

  The Genotyping Kit for target alleles supports rapid PCR amplification of genomic DNA across diverse sample types. This article examines how single-tube DNA extraction can strengthen evidence interpretation without confusing genotype, expression, and disease-mechanism findings.

8598 records 1/574 page Next 12345 下5页 Last page